CIS BIOPHARMA

CIS BIOPHARMA is a biotechnology company dedicated to revolutionizing cancer treatment through novel targeted therapies. We are in the area of Basel, Switzerland, a global hub for life sciences innovation. In our state-of-the-art laboratories, we pioneer groundbreaking technology to change the standard-of-care in oncology, addressing cancer with high unmet need, such as lung cancer and brain tumors. CIS BIOPHARMA has developed capabilities for creating targeted cancer therapies, leveraging our expertise in protein engineering, linker chemistry, and bioconjugation of potent cancer drugs in our high containment laboratory. Our pipeline products include ADCs and radioligand therapies for cancer patients with poor prognosis and prone to high spread of metastases. Our assets include targeting moieties against CD 171 and CD 276. Incorporated by successful biopharmaceutical entrepreneurs, our executive and science team has a vast track record in developing cancer drugs, from discovery to clinical validation, approval and launch. They have executed their skills for corporates such as Novartis, Roche, Amgen, Merck and Pfizer. For more information visit our new webhome www.cisbiopharma.com